No pain, just gain: Painless, easy, and fast dried blood spot collection from fingertip and upper arm in doping control
Solheim et al.
The finding, in our words
In 108 Danish national-level athletes across different sports, both fingertip DBS collected with HemaSpot HF and upper-arm DBS collected with Tasso-M20 received low pain scores and very good general experience ratings, with upper-arm sampling rated as slightly less painful than fingerprick. This supports the acceptability of decentralised blood microsampling for doping control across diverse athlete populations including para-athletes.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This study compared four dried blood spot devices for glucocorticoid detection, finding that the Mitra VAMS device offered the best combination of analytical recovery and user usability, whilst the HemaXis DB10 showed the least bias compared to whole blood.
The analysis indicates that dried blood spots and volumetric absorptive microsampling enable minimally invasive monitoring of prohibited substances, with volumetric absorptive microsampling offering improved quantitative reliability over traditional dried spots.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
The study found that although participants preferred patient-centric microsampling devices for home use, the agreement with venous plasma for measuring CRP and cytokines was inconsistent, indicating that further validation is required before these methods replace standard venipuncture.
In a 20-person proof-of-concept pilot among veterans with HIV, remote self-collection of dried blood spots for phosphatidylethanol monitoring was feasible and acceptable, with high return and analysis rates and positive feedback; a small first step toward decentralised alcohol biomarker monitoring rather than proof of it.